Insmed INSM 深 滬
等待開盤 09-17 09:30:00 美东时间
122.58
+2.660
+2.22%
華盛通- 最 高124.41
- 今 開120.00
- 成交量 143.37万股
- 最 低 119.55
- 昨 收 119.92
- 總市值 267.69亿
- 52周最高 212.75
- 市盈率 靜 --
- 換手率 0.66%
- 52周最低 90.39
- 委 比 97.57%
- 總股本 2.18亿
- 歷史最高 212.75
- 量 比 0.59
- 振 幅 4.05%
- 歷史最低 2.64
- 每 手 1
- 風險率 30.47%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 巴克莱大幅升Strategy目标价至160美元！康宁遭看淡至180美元，较现价仍溢价25%
今日重点评级关注：HC Wainwright & Co.：上调Cardiff Oncology评级至"买入"，目标价9美元；古根海姆：维持Inventiva"买入"评级，目标价从11美元升至14美元
09-16 16:10
Roth Capital Reiterates Buy on Insmed, Lowers Price Target to $198
Roth Capital analyst Adam Walsh reiterates Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $212 to $198.
09-16 00:40
Goldman rebalances its long duration stock basket
The Goldman Sachs equity team has rebalanced its Long Duration Basket amid rising interest rates. Equities usually struggle to digest sharp increases in interest rates, with long duration growth stock...
09-13 22:12
Here's How Much $100 Invested In Insmed 5 Years Ago Would Be Worth Today
Insmed (NASDAQ:INSM) has outperformed the market over the past 5 years by 24.42% on an annualized basis producing an average annual return of 35.99%. Currently, Insmed has a market capitalization of $27.58 billion. Buying $100 In INSM: If an investor had bought $100 of INSM stock 5 years ago, it wou...
09-08 04:45
If You Invested $1000 In Insmed Stock 10 Years Ago, You Would Have This Much Today
Insmed (NASDAQ:INSM) has outperformed the market over the past 10 years by 10.74% on an annualized basis producing an average annual return of 24.29%. Currently, Insmed has a market capitalization of $26.34 billion. Buying $1000 In INSM: If an investor had bought $1000 of INSM stock 10 years ago, it...
08-28 23:30
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
Wells Fargo Maintains Overweight on Insmed, Raises Price Target to $169
Wells Fargo analyst Benjamin Burnett maintains Insmed (NASDAQ:INSM) with a Overweight and raises the price target from $161 to $169.
08-07 21:56
美股牛股 | 心血管药企BRVE上市首日飙涨逾65%，超预期募资3.8亿美元；IOVA大涨逾43%，赫兹租车涨近30%
心血管药企BRVE上市首日飙涨逾65%，超预期募资3.8亿美元；IOVA大涨逾43%，Q2亏损大幅收窄；赫兹租车涨近30%，Q2净利实现扭亏为盈>>
08-07 18:53
